Evaluation of Patients With Covid-19 Infection in Terms of Severity of Osteoprosis : Kayseri City (Education and Research) Hospital
Osteoporosis is a condition characterized by decreased bone strength and an increased risk of fracture. Age, gender, body mass index, fragility fracture history, corticosteroid use, immobilization, smoking and alcohol use, endocrine pathologies besides inflammatory and infectious pathologies can also be effective in the development of osteoporosis. The aim of the study is to evaluate the effect of Covid-19 infection on the development of osteoporosis.In this study, bone mineral density (BMD) measurements of patients with Covid-19 infection were examined. For this, dual-energy x-ray absorptiometry (DEXA) measurement was used. A total of 55 patients were included in the study and data such as age, height, weight, comorbidities, drugs used, and treatment methods were recorded. Results showed that the time spent in the intensive care unit was associated with the femoral neck T score in DEXA measurements of patients with Covid-19 infection. The use of drugs such as alendronate, zolendronate, denosumab or teriparatide during the treatment process did not have a statistically significant effect on the lumbar and femur T scores..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 15. Aug. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: August 15, 2023, Last downloaded: ClinicalTrials.gov processed this data on August 23, 2023, Last updated: August 23, 2023 |
---|
Study ID: |
NCT05993130 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG00939110X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG00939110X | ||
003 | DE-627 | ||
005 | 20230823010719.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230816s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG00939110X | ||
035 | |a (UBBS_Klinische_Studien)NCT05993130 | ||
035 | |a (UBBS_Klinische_Studien)Kayseri City Hospital | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Evaluation of Patients With Covid-19 Infection in Terms of Severity of Osteoprosis |b Kayseri City (Education and Research) Hospital |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: August 15, 2023, Last downloaded: ClinicalTrials.gov processed this data on August 23, 2023, Last updated: August 23, 2023 | ||
520 | |a Osteoporosis is a condition characterized by decreased bone strength and an increased risk of fracture. Age, gender, body mass index, fragility fracture history, corticosteroid use, immobilization, smoking and alcohol use, endocrine pathologies besides inflammatory and infectious pathologies can also be effective in the development of osteoporosis. The aim of the study is to evaluate the effect of Covid-19 infection on the development of osteoporosis.In this study, bone mineral density (BMD) measurements of patients with Covid-19 infection were examined. For this, dual-energy x-ray absorptiometry (DEXA) measurement was used. A total of 55 patients were included in the study and data such as age, height, weight, comorbidities, drugs used, and treatment methods were recorded. Results showed that the time spent in the intensive care unit was associated with the femoral neck T score in DEXA measurements of patients with Covid-19 infection. The use of drugs such as alendronate, zolendronate, denosumab or teriparatide during the treatment process did not have a statistically significant effect on the lumbar and femur T scores. | ||
650 | 4 | |a Study Type: Observational | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 15. Aug. |
773 | 1 | 8 | |g year:2023 |g day:15 |g month:08 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05993130 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 15 |c 08 |